Catherine Piveteau

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
No aliases are listed.
Publication record
46 papers · 1,258 citations · H-index 17

PAPERS

ERAP2 inhibitor -incorporated nanofibers: Characterization and biological assessment.
20260 citationsauthor #4
Optimizing the Antibiotic Potency and Metabolic Stability of Pyridomycin Using a Semisynthetic Approach.
20260 citationsauthor #10
Pulmonary delivery of clofoctol-loaded nanoparticles inhibits SARS-CoV-2 replication and reduces pneumonia.
20252 citationsauthor #12
A new chemotype that opens the S2∗ pocket of the 3CL protease exhibits antiviral activity against SARS-CoV-2.
20250 citationsauthor #9
Selective accumulation of nanoparticles in infected cells for targeted drug delivery.
20250 citationsauthor #12
Molecular mechanism of a triazole-containing inhibitor of Mycobacterium tuberculosis DNA gyrase
20244 citationsauthor #9
Optimization of pyridylpiperazine-based inhibitors of the Escherichia coli AcrAB-TolC efflux pump.
20236 citationsauthor #6
Discovery, Structure-Activity Relationships, and In Vivo Activity of Dihydropyridone Agonists of the Bile Acid Receptor TGR5.
20237 citationsauthor #13
Regioselective and Stereoselective Synthesis of Parthenolide Analogs by Acyl Nitroso-Ene Reaction and Their Biological Evaluation against Mycobacterium tuberculosis
20232 citationsauthor #6
Migration study of phthalates from non-food plastic containers used in food preservation
202315 citationsauthor #4
Exploring the Antitubercular Activity of Anthranilic Acid Derivatives: From MabA (FabG1) Inhibition to Intrabacterial Acidification
20233 citationsauthor #4
Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses
202316 citationsauthor #11
Pyridylpiperazine efflux pump inhibitor boosts in vivo antibiotic efficacy against K. pneumoniae
202316 citationsauthor #10
Rapid and Efficient Access to Novel Bio-Inspired 3-Dimensional Tricyclic SpiroLactams as Privileged Structures via Meyers’ Lactamization
20231 citationsauthor #3
Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice
20229 citationsauthor #14
Tricyclic SpiroLactams Kill Mycobacteria In Vitro and In Vivo by Inhibiting Type II NADH Dehydrogenases
202215 citationsauthor #10
Exposure to Bisphenols from Baby Bottles and Non-Food Containers Used for Food Preservation in Cameroon
20220 citationsauthor #3
Optimization of 1,2,4-Triazole-3-thiones toward Broad-Spectrum Metallo-β-lactamase Inhibitors Showing Potent Synergistic Activity on VIM- and NDM-1-Producing Clinical Isolates.
202218 citationsauthor #15
Discovery of the First Selective Nanomolar Inhibitors of ERAP2 by Kinetic Target‐Guided Synthesis
202217 citationsauthor #15
Small-molecule SMARt751 hypersensitizes M. tuberculosis resistant to ethionamide by upregulating the mymA operon
20221 citationsauthor #19
The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis
202223 citationsauthor #19
Identification of indole-based activators of insulin degrading enzyme.
20216 citationsauthor #12
Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice
20214 citationsauthor #14
Hypothalamic bile acid-TGR5 signaling protects from obesity.
2021166 citationsauthor #11
Beyond the Rule of 5: Impact of PEGylation with Various Polymer Sizes on Pharmacokinetic Properties, Structure-Properties Relationships of mPEGylated Small Agonists of TGR5 Receptor.
20219 citationsauthor #7
High-Throughput Image-Based Aggresome Quantification
20209 citationsauthor #5
Modulators of hERAP2 discovered by high-throughput screening.
202014 citationsauthor #7
Fragment-based optimized EthR inhibitors with in vivo ethionamide boosting activity.
202019 citationsauthor #7
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening.
202019 citationsauthor #9
Drug Target Engagement Using Coupled Cellular Thermal Shift Assay—Acoustic Reverse-Phase Protein Array
201912 citationsauthor #6
Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
20180 citationsauthor #8
Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbα antagonism: a single-centre propensity-matched cohort study and a randomised study.
2018268 citationsauthor #14
Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
20180 citationsauthor #8
Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance.
201751 citationsauthor #5
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
201783 citationsauthor #8
Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox.
201744 citationsauthor #3
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
20172 citationsauthor #8
Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice
201576 citationsauthor #24
In vivo efficacy of microbiota-sensitive coatings for colon targeting: a promising tool for IBD therapy.
201543 citationsauthor #4
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches.
201466 citationsauthor #7
Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737
201417 citationsauthor #8
Chute of including road safety
20130 citationsauthor #1
Structure-activity relationships and blood distribution of antiplasmodial aminopeptidase-1 inhibitors.
201236 citationsauthor #3
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
201175 citationsauthor #7
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
201186 citationsauthor #7
Iso CombretaQuinolines : First multi-target molecules in cancer therapy with unprecedented antivascular and immunomodulatory activities
year unknown0 citationsauthor #9

TIMELINE

2011 161 citations

2012 36 citations

2013 0 citations

2014 83 citations

2015 119 citations

2017 180 citations

2018 268 citations

2019 12 citations

2020 61 citations

2021 185 citations

2022 83 citations

2023 66 citations

2024 4 citations

2025 2 citations

2026 0 citations

Unknown 0 citations

Catherine Piveteau

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT